Substituted phenyl boronic acid containing polymers and methods of use

Abstract

The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

1 . A polymer comprising a repeat unit of Formula (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein
 R 1 , R 2 , and R 3  are independently hydrogen or optionally substituted alkyl; 
 Y 1  is a direct bond, —NR 9 , —NR 9 -A 1 -L 2 -A 2 -, —NC(O)-A 1 -L 2 -A 2 -, -L 1 -A 1 -NR 9 -A 2 -, -L 1 -A 1 -O-A 2 -, or -L 1 -A 1 -S-A 2 -; 
 each L 1  is independently —NR 9 —, —NC(O)— or —C(O)N—; 
 each L 2  is independently absent, —NR 9 —, —O— or —S—; 
 each A 1  and A 2  is independently absent or optionally substituted C 1 -C 5  alkylene; 
 Z is 
 
       
         
           
           
               
               
           
         
         each X 1  and X 2  is independently selected from a group consisting of hydrogen, halo, —CN, —NO 2 , —N + (R 9 )(R 10 )(R 11 ), —CF 3 , —SO 3 (R 9 ), —SO 2 (R 9 ), —CON(R 9 )(R 10 ), —(CH 2 ) m —N(R 9 )(R 10 ), and —OR 9 ; 
         each R 9 , R 10  and R 11  is independently hydrogen or optionally substituted alkyl; 
         n is an integer from 1 to 100,000; and 
         m is an integer from 0 to 4; 
         with the proviso that no more than one of X 1  and X 2  is hydrogen, and when either X 1  or X 2  is —(CH 2 ) m —N(R 9 )(R 10 ), it is bonded to the carbon atom in the phenyl ring of Z that is adjacent to the carbon atom in the phenyl ring to which —B(OH) 2  is bonded, and the other of X 1  and X 2  is hydrogen. 
       
     
     
         2 . (canceled) 
     
     
         3 . The polymer of  claim 1 , wherein the repeat unit of Formula (I) is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       pharmaceutically acceptable salts thereof. 
     
     
         4 . The polymer of  claim 1 , wherein R 1 , R 2  and R 3  are each independently hydrogen. 
     
     
         5 . The polymer of  claim 1 , wherein X 1  and X 2  are each independently selected from a group consisting of hydrogen, halo, and —CF 3 , with the proviso that no more than one of X 1  and X 2  is hydrogen. 
     
     
         6 - 9 . (canceled) 
     
     
         10 . The polymer of  claim 1 , further comprising at least one repeat unit selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof, where n is an integer from 1 to 
     
     
         11 . The polymer of  claim 1 , selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof. 
     
     
         12 - 17 . (canceled) 
     
     
         18 . A method for treating a metabolic disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer of  claim 1 . 
     
     
         19 . The method of  claim 18 , further comprising administering another therapeutic agent to the subject in need thereof. 
     
     
         20 . The method of  claim 18 , wherein the metabolic disorder is glucose intolerance, type-1 diabetes mellitus (T1DM), type-2 diabetes mellitus (T2DM), prediabetes, hyperlipidemia, obesity, overweight, dyslipidemia, hypertension, hyperglycemia, impaired glucose tolerance, insulin resistance, metabolic syndrome, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), or polycystic ovary syndrome (PCOS). 
     
     
         21 . The method of  claim 18 , wherein the metabolic disorder is type-2 diabetes mellitus. 
     
     
         22 . (canceled) 
     
     
         23 . The method of  claim 18 , wherein the metabolic disorder is obesity. 
     
     
         24 . A method for treating a metabolic disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer of  claim 11 . 
     
     
         25 . The method of  claim 24 , wherein the metabolic disorder is type-2 diabetes mellitus. 
     
     
         26 . The method of  claim 24 , wherein the metabolic disorder is obesity. 
     
     
         27 . The polymer of  claim 1 , wherein at least one of X 1  and X 2  is fluoro. 
     
     
         28 . The polymer of  claim 1 , wherein the —B(OH) 2  group is at the 4-position of the phenyl ring of Z, with respect to Y 1 . 
     
     
         29 . The polymer of  claim 1 , comprising the structure 
       
         
           
           
               
               
           
         
       
     
     
         30 . A method for treating a metabolic disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer of  claim 29 . 
     
     
         31 . The method of  claim 29 , wherein the metabolic disorder is type-2 diabetes mellitus. 
     
     
         32 . The method of  claim 29 , wherein the metabolic disorder is obesity.